ALC-0315
外觀
ALC-0315 | |
---|---|
IUPAC名 [(4-Hydroxybutyl)azanediyl]di(hexane-6,1-diyl) bis(2-hexyldecanoate) | |
識別 | |
CAS號 | 2036272-55-4 |
PubChem | 122666778 |
ChemSpider | 103867294 |
SMILES |
|
性質 | |
化學式 | C48H95NO5 |
摩爾質量 | 766.27 g·mol−1 |
密度 | 0.919±0.06 g·cm−3(20 °C)[1] |
溶解性(水) | 7.7×10−5 g·L−1(25 °C)[1] |
若非註明,所有數據均出自標準狀態(25 ℃,100 kPa)下。 |
ALC-0315是一種合成脂,為油狀物質。它是BioNTech和輝瑞的SARS-CoV-2疫苗和BNT162b2疫苗的賦形劑,為脂質納米顆粒(LNP)的四成分之一,LNP封裝並保護了藥物中脆弱的有效成分mRNA。[2][3]
在體內pH下,ALC-0315帶正電荷,它可以和帶負電荷的mRNA相互作用。[4]這些納米顆粒在體外和體內都可以促進核酸(如寡核苷酸或信使RNA)的吸收。[5][6]
合成
[編輯]ALC-0315的合成方法如下:
參見
[編輯]參考文獻
[編輯]- ^ 1.0 1.1 Calculated using Advanced Chemistry Development (ACD/Labs) Software V11.02 ([C] 1994-2021 ACD/Labs). Retrieved from SciFinder.
- ^ Michael McCoy. Lipids, the unsung COVID-19 vaccine component, Get Investment. Chemical and Engineering News. February 12, 2021.
- ^ Ryan Cross. Without These Lipid Shells, There Would Be No mRNA Vaccines for COVID-19. Chemical & Engineering News. 2021: 16–19. doi:10.47287/cen-09908-feature1.
- ^ Medicines and Healthcare products Regulatory Agency. Public Assessment Report: Authorisation for Temporary Supply COVID-19 mRNA Vaccine BNT162b2 (PDF). 11 December 2020 [2021-05-30]. (原始內容 (PDF)存檔於2020-12-16).
- ^ mRNA-based therapeutics — developing a new class of drugs (頁面存檔備份,存於網際網路檔案館), Ugur Sahin, Katalin Karikó and Özlem Türeci, Nature Reviews Drug Discovery, 13, 759-780 (2014), doi:10.1038/nrd4278.
- ^ mRNA vaccines — a new era in vaccinology (頁面存檔備份,存於網際網路檔案館), Norbert Pardi, Michael J. Hogan, Frederick W. Porter and Drew Weissman, Nature Reviews Drug Discovery, 17, 261-279 (2018), doi:10.1038/nrd.2017.243.
外部連結
[編輯]- WIPO patent WO 2018/081480 A1 (頁面存檔備份,存於網際網路檔案館) - occurs as compound III-3.